Browsing by Author "Verma, Saloni"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item ALK and ERBB2 Protein Inhibition is Involved in the Prevention of Lung Cancer Development by Vincamine(Bentham Science Publishers, 2023-04-13T00:00:00) Verma, Aarti; Yadav, Poonam; Rajput, Sonu; Verma, Saloni; Arora, Sahil; Kumar, Raj; Bhatti, Jasvinder Singh; Khurana, Amit; Navik, UmashankerBackground: According to the WHO report of 2022, 2.21 million new cases and 1.80 million deaths were reported for lung cancer in the year 2020. Therefore, there is an urgent need to explore novel, safe, and effective therapeutic interventions for lung cancer. Objective: To find the potential targets of vincamine using a network pharmacology approach and docking studies and to evaluate the anti-cancer effect of vincamine on A549 cell line. Methods: Hence, in the present study, we explored the anti-cancer potential of vincamine by using network pharma-cology, molecular docking, and in vitro approaches. Network pharmacology demonstrated that the most common targets of vincamine are G-protein coupled receptors, cytosolic proteins, and enzymes. Among these targets, two targets, ALK and ERBB2 protein, were common between vincamine and non-small cell lung cancer. Results: We discovered a link between these two targets and their companion proteins, as well as cancer-related pathways. In addition, a docking investigation between the ligand for vincamine and two targeted genes revealed a strong affinity toward these targeted proteins. Further, the in vitro study demonstrated that vincamine treatment for 72 h led to dose-dependent (0-500 ?M) cytotoxicity on the A549 lung cancer cell line with an IC50 value of 291.7 ??. The wound-healing assay showed that vincamine treatment (150 and 300 ?M) significantly inhibited cell migration and invasion. Interestingly, acridine orange/ethidium bromide dual staining demonstrated that vincamine treatment induces apoptosis in A549 cells. Additionally, the dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay showed an increased level of reactive oxygen species (ROS) after the vincamine treatment, indicating ROS-mediated apoptosis in A549 cells. Conclusion: Altogether, based on our findings, we hypothesize that vincamine-induced apoptosis of lung cancer cells via ALK and ERBB2 protein modulation may be an attractive futuristic strategy for managing lung cancer in combination with chemotherapeutic agents to obtain synergistic effects with reduced side effects. � 2023 Bentham Science Publishers.Item Microbiome in Pulmonary Tuberculosis(Springer Nature, 2022-03-25T00:00:00) Rakshit, Arnab; Verma, Aarti; Verma, Saloni; Bhatti, Gurjit Kaur; Khurana, Amit; Bhatti, Jasvinder Singh; Jawalekar, Snehal Sainath; Navik, UmashankerTuberculosis (TB) is among the global dominant fatal infection caused by a single organism, and it is still holding its position in spite of the golden age of the antibiotics. The recent studies are mostly focused on finding the prevention of TB rather than curing it because the antimycobacterial chemotherapy is failing constantly due to emerging multidrug resistance (MDR). Further, the intestinal microbiota is the central command for maintaining the homeostasis of the microbial profile of different organs. The change in the intestinal microbiota effects homeostasis by impacting the immune response to the microbial profile of various organs. Thus, it also affects the chance of contracting the infections. Here in this chapter, it is mostly focused on the reason behind the TB getting chance to infect the healthy lung tissue. It is also found that dysbiosis in gut microbiota, which directly affects the lung, plays a key role in giving TB a chance to hold its ground. It also highlights the new curative method which we can apply by correcting the gut microbial profile, which in turn corrects the lung microbial profile and rest of the function will done by body�s own immune system. It is thus found that proper restoration of the microbial profile enhances the immune response and could restore the homeostasis. � The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd. 2022.